肝脾T细胞淋巴瘤成功行挽救性单倍体造血干细胞移植一例报告并文献复习

Salvage haploidentical hematopoietic stem cell transplantation for hepatosplenic T-cell lymphoma:a case report and literature review

目的探讨肝脾T细胞淋巴瘤(hepatosplenic T-cell lymphoma,HSTCL)的临床特征、诊断、治疗进展及挽救性造血干细胞在治疗HSTCL中的作用。方法报告航天中心医院1例挽救性单倍体造血干细胞移植(hematopoietic stem cell transplantation,HSCT)成功治疗罕见的αβ型HSTCL,回顾分析临床及实验室检查资料,并全面复习相关文献。结果患者移植后21 d(+21 d)白细胞植入,+32 d血小板植入,移植后未出现明显急性移植物抗宿主病,评估处于持续缓解状态,移植术后随访9个月余,无广泛慢性移植物抗宿主病表现,生存质量良好。结论HSTCL需考虑造血干细胞移植治疗,改良预处理方案的挽救性异基因造血干细胞移植(allo-HSCT)有实际应用价值。

Objective To explore the clinical features,diagnosis and treatment of hepatosplenic T-cell lymphoma(HSTCL)and the role of salvage hematopoietic stem cells in treating HSTCL.Methods A successful treatment of one case with rareαβtype HSTCL by salvage haploidentical hematopoietic stem cell transplantation(HSCT)was reported whose relevant clinical and laboratory examination data were fully analyzed.Relevant literatures were comprehensively reviewed.Results The leukocyte was implanted at+21 day after HSCT,while the platelet was implanted at+32 day after HSCT.The patient did not experience any obvious acute graft-versus-host disease.The evaluation results indicated that the patient remitted continuously.The patient had been followed up for more than nine months after transplantation.The patient did not have any extensive chronic graft-versus-host disease and had good quality of life.Conclusions HSTCL is a rare malignant tumor of the hematopoietic system.HSCT should be considered.The salvage allo-HSCT with improved pre-treatment regimen has its practical application value.